These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

852 related items for PubMed ID: 23625945

  • 1. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
    Krum H, Shi H, Pitt B, McMurray J, Swedberg K, van Veldhuisen DJ, Vincent J, Pocock S, Zannad F, EMPHASIS-HF Study Group.
    Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators.
    J Am Coll Cardiol; 2013 Oct 22; 62(17):1585-93. PubMed ID: 23810881
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA, CHARM Investigators.
    Eur J Heart Fail; 2008 Feb 22; 10(2):157-63. PubMed ID: 18242128
    [Abstract] [Full Text] [Related]

  • 4. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS.
    Am J Cardiovasc Drugs; 2010 Feb 22; 10(1):55-63. PubMed ID: 20104935
    [Abstract] [Full Text] [Related]

  • 5. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC.
    J Card Fail; 2012 Apr 22; 18(4):265-81. PubMed ID: 22464767
    [Abstract] [Full Text] [Related]

  • 6. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F.
    Circ Heart Fail; 2014 Jan 22; 7(1):51-8. PubMed ID: 24297687
    [Abstract] [Full Text] [Related]

  • 7. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).
    Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B.
    Eur J Heart Fail; 2010 Jun 22; 12(6):617-22. PubMed ID: 20388647
    [Abstract] [Full Text] [Related]

  • 8. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
    Krum H, Mohacsi P, Katus HA, Tendera M, Rouleau JL, Fowler MB, Coats AJ, Roecker EB, Packer M, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.
    Am Heart J; 2006 Jan 22; 151(1):55-61. PubMed ID: 16368292
    [Abstract] [Full Text] [Related]

  • 9. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
    Collier TJ, Pocock SJ, McMurray JJ, Zannad F, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B.
    Eur Heart J; 2013 Sep 22; 34(36):2823-9. PubMed ID: 23864130
    [Abstract] [Full Text] [Related]

  • 10. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
    Cohen Solal A, Leurs I, Assyag P, Beauvais F, Clerson P, Contre C, Thebaut JF, Genoun M, French National College of Cardiologists.
    Arch Cardiovasc Dis; 2012 Sep 22; 105(6-7):355-65. PubMed ID: 22800720
    [Abstract] [Full Text] [Related]

  • 11. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
    Pölzl G, Gouya G, Hügel H, Frick M, Ulmer H, Pachinger O.
    Wien Klin Wochenschr; 2002 Oct 31; 114(19-20):833-9. PubMed ID: 12503474
    [Abstract] [Full Text] [Related]

  • 12. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Preiss D, van Veldhuisen DJ, Sattar N, Krum H, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Zannad F, McMurray JJ.
    Eur J Heart Fail; 2012 Aug 31; 14(8):909-15. PubMed ID: 22611047
    [Abstract] [Full Text] [Related]

  • 13. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.
    N Engl J Med; 2003 Apr 03; 348(14):1309-21. PubMed ID: 12668699
    [Abstract] [Full Text] [Related]

  • 14. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
    Verbrugge FH, Duchenne J, Bertrand PB, Dupont M, Tang WH, Mullens W.
    Am J Cardiol; 2013 Dec 15; 112(12):1913-20. PubMed ID: 24286620
    [Abstract] [Full Text] [Related]

  • 15. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA, Konstam MA.
    Circ Heart Fail; 2010 May 15; 3(3):347-53. PubMed ID: 20299607
    [Abstract] [Full Text] [Related]

  • 16. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators.
    Am Heart J; 2006 May 15; 151(5):985-91. PubMed ID: 16644319
    [Abstract] [Full Text] [Related]

  • 17. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
    Dimopoulos K, Salukhe TV, Coats AJ, Mayet J, Piepoli M, Francis DP.
    Int J Cardiol; 2004 Feb 15; 93(2-3):105-11. PubMed ID: 14975535
    [Abstract] [Full Text] [Related]

  • 18. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
    Gheorghiade M, Khan S, Blair JE, Harinstein ME, Krum H, Mukherjee R, Pitt B, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival (EPHESUS) Investigators.
    Am Heart J; 2009 Sep 15; 158(3):437-43. PubMed ID: 19699868
    [Abstract] [Full Text] [Related]

  • 19. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
    Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Gheorghiade M, Inge PJ, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN.
    Circ Heart Fail; 2010 Sep 15; 3(5):596-605. PubMed ID: 20634483
    [Abstract] [Full Text] [Related]

  • 20. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations.
    Rogers JK, McMurray JJ, Pocock SJ, Zannad F, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B.
    Circulation; 2012 Nov 06; 126(19):2317-23. PubMed ID: 23042980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.